Applied Genetic Technologies Corporation (AGTC) Given Outperform Rating at Wedbush

Applied Genetic Technologies Corporation (NASDAQ:AGTC)‘s stock had its “outperform” rating restated by stock analysts at Wedbush in a report released on Wednesday, November 8th. They presently have a $9.00 price objective on the biotechnology company’s stock. Wedbush’s target price suggests a potential upside of 133.77% from the stock’s current price. Wedbush also issued estimates for Applied Genetic Technologies’ Q2 2018 earnings at ($0.01) EPS, FY2020 earnings at $1.22 EPS and FY2021 earnings at $1.11 EPS.

AGTC has been the subject of a number of other reports. HC Wainwright set a $16.00 price target on shares of Applied Genetic Technologies and gave the stock a “buy” rating in a research report on Thursday, August 10th. Stifel Nicolaus dropped their price target on shares of Applied Genetic Technologies from $15.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, September 14th. Cantor Fitzgerald dropped their price target on shares of Applied Genetic Technologies from $15.00 to $9.00 and set a “neutral” rating for the company in a research report on Thursday, September 14th. Zacks Investment Research upgraded shares of Applied Genetic Technologies from a “sell” rating to a “hold” rating in a research report on Tuesday, July 25th. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $7.00 price target (down from $14.00) on shares of Applied Genetic Technologies in a research report on Thursday, September 14th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $10.17.

Shares of Applied Genetic Technologies (AGTC) opened at $3.85 on Wednesday. Applied Genetic Technologies has a 12-month low of $3.25 and a 12-month high of $10.15.

Applied Genetic Technologies (NASDAQ:AGTC) last announced its earnings results on Wednesday, September 13th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.22 by ($0.40). The business had revenue of $8.30 million for the quarter, compared to the consensus estimate of $12.39 million. Applied Genetic Technologies had a negative net margin of 8.78% and a negative return on equity of 2.86%. The business’s quarterly revenue was down 31.4% compared to the same quarter last year. During the same quarter last year, the firm posted $0.15 earnings per share. equities analysts forecast that Applied Genetic Technologies will post -1.14 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Applied Genetic Technologies by 250.2% in the first quarter. Dimensional Fund Advisors LP now owns 159,883 shares of the biotechnology company’s stock worth $1,103,000 after buying an additional 114,230 shares in the last quarter. Morgan Stanley lifted its holdings in shares of Applied Genetic Technologies by 27.3% in the first quarter. Morgan Stanley now owns 168,256 shares of the biotechnology company’s stock worth $1,162,000 after buying an additional 36,117 shares in the last quarter. Prudential Financial Inc. raised its stake in Applied Genetic Technologies by 24.2% during the first quarter. Prudential Financial Inc. now owns 155,210 shares of the biotechnology company’s stock valued at $1,071,000 after purchasing an additional 30,200 shares in the last quarter. Ativo Capital Management LLC purchased a new stake in Applied Genetic Technologies during the second quarter valued at $439,000. Finally, Wells Fargo & Company MN raised its stake in Applied Genetic Technologies by 1.1% during the first quarter. Wells Fargo & Company MN now owns 19,005 shares of the biotechnology company’s stock valued at $131,000 after purchasing an additional 200 shares in the last quarter. 53.02% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “Applied Genetic Technologies Corporation (AGTC) Given Outperform Rating at Wedbush” was first reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://baseballnewssource.com/markets/applied-genetic-technologies-corporation-agtc-given-outperform-rating-at-wedbush/1767716.html.

About Applied Genetic Technologies

Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).

Analyst Recommendations for Applied Genetic Technologies (NASDAQ:AGTC)

Receive News & Ratings for Applied Genetic Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Jack Morris, Alan Trammel Voted by Modern Era Committee into Hall of Fame
Yankees and Marlins Continue Stanton Trade Talks
Yankees and Marlins Continue Stanton Trade Talks
Marlins Making Moves, Trade Dee Gordon to Seattle
Marlins Making Moves, Trade Dee Gordon to Seattle
Report: Astros Dallas Keuchel Pitched With Injured Foot
Report: Astros Dallas Keuchel Pitched With Injured Foot
Angels Sign Former Prospect with Braves Kevin Maitan
Angels Sign Former Prospect with Braves Kevin Maitan
Shohei Ohtani Has Turned Down Red Sox and Yankees
Shohei Ohtani Has Turned Down Red Sox and Yankees


Leave a Reply

 
© 2006-2017 BBNS.